NICE recommends Xgeva (Amgen/GSK) for SRE prevention of Solid Tumors

NICE, The National Institute for Health and Clinical Excellence, has issued draft guidance recommending the use of human monoclonal antibody Xgeva (denosumab) from Amgen/GSK for for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) for those with bone metastasis from breast cancer, patients with painful bone metastasis from hormone-refractory prostate cancer for whom other treatments (including analgesics and palliative radiotherapy) have failed as well as for people with bone metastasis from other solid tumours for whom zoledronic acid is indicated.